Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects

8 Jun 2020

Abstract excerpt

Introduction Phenytoin is a frequently used drug treatment for epilepsy. Genetic polymorphisms in the metabolism of phenytoin, particularly CYP2C9, are strongly associated with increased plasma concentrations and can result in toxicity. Human leukocyte antigen (HLA) alleles are well-known genetic predictors of certain antiepileptic drug-associated severe cutaneous adverse reactions (SCAR), including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biosimilars and Bioanalytical Methods
Share to Drug-Induced Adverse Reactions

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32510242
DOI: 10.1080/17425255.2020.1780209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effectsPMID 32510242Read ↗

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.Semantic proximity Read ↗

Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.Semantic proximity Read ↗

CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.Semantic proximity Read ↗

Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in PeruSemantic proximity Read ↗

Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis.Semantic proximity Read ↗

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatmentSemantic proximity Read ↗

Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.Semantic proximity Read ↗

Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population.Semantic proximity Read ↗

Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population.Semantic proximity Read ↗

HLA Alleles and CYP 2C9*3 as Predictors of Phenytoin Hypersensitivity in East AsiansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.